Результаты поиска

IgA plasma cell leukemia.

Plasma cell leukemia (PCL) is a rare entity. There are two presentations of PCL, primary or secondary. The primary or de novo form of PCL presents with an acute and rapidly progressive leukemic phase. This form occurs when the patient has no pre-existing multiple myeloma (MM). The secondary form is the most advanced form of MM. The PCL is a rare disorder representing 1-2% of the diagnosed cases of MM. Median age at presentation is usually above 50 years. The monoclonal protein in patients with PCL may be IgG (50%), IgA (15%), or in rare cases IgD or IgE (6%). We report a case of IgA primary PC

Совпадение в полном тексте источника
… Liver and renal function tests showed hypoalbuminemia, hyperuricemia, and raised serum creatinine. Serum protein electrophoresis and immunofixation studies showed IgA 2 950 mg/dl, IgG 628 mg/dl, IgM 16.1 mg/dl, and IgA kappa paraprotein at a concentration of 2.95 g/dl. …

Молодой мужчина с повреждениями почек в результате генетической митохондриальной болезни: доклад о конкретных случаях и обзор литературы.

Наиболее знакомым синдромом ушей и почек является синдром Алпорта для нефролога. Мутации в митохондриальном гене MT-TL1, который кодирует UUR, может также вызывать почечную дисфункцию и потерю слуха. В этом исследовании мы сообщили о молодом китайском мужчине с белковой и почечной дисфункцией с морфологической презентацией фокусного сегментального гломерулосклероза (FSGS) с m.3243 A > G мутация в митохондрии в митохондриальном гене MT-TL1. Мы провели систематический обзор литературы в целях обобщения ранее сообщенных случаев. 17-year-old Мужчина был доставлен в нашу больницу из-за пенистых моч

Совпадение в полном тексте источника
… Published cases mainly involve adolescents with proteinuria, renal insufficiency and hyperuricemia, without obvious hematuria. Abnormal mitochondria in podocytes and renal tubules are the typical ultrastructural changes, and most lesions are classified as FSGS-NOS. … Febuxostat targeted hyperuricemia to avoid further renal injury. …

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.

In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m2), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3 + 3 dose escalation based on dose-limiting toxicities (DLTs) was employed in phase I (total 15); 2/6 patients developed DLTs (neutropenia and thrombocytopenia) at dose level 3 establishing the recommended phase II dose as bendamustine 80 mg/m2, ixazomib 4 mg, and dexamethasone 40 mg. The median age was 67 years (range, 42-72

Совпадение в полном тексте источника
… 3 2 1 Anemia 1 1 12 6 2 0 Thrombocytopenia 3 0 13 8 6 2 Lymphopenia 3 3 19 17 4 2 Leukopenia 2 1 12 4 3 1 Non-hematologic Nausea 2 0 10 0 4 0 Diarrhea 1 0 8 2 2 0 Anorexia 1 0 7 0 2 0 Increased AST/ALT 2 0 0 0 2 0 Increased creatinine 0 0 3 0 1 0 Hypophosphatemia 0 0 6 1 2 0 Hypokalemia 0 0 5 1 0 0 Hyperuricemia … | 1 | 12 | 4 | 3 | 1 Non-hematologic Nausea | 2 | 0 | 10 | 0 | 4 | 0 Diarrhea | 1 | 0 | 8 | 2 | 2 | 0 Anorexia | 1 | 0 | 7 | 0 | 2 | 0 Increased AST/ALT | 2 | 0 | 0 | 0 | 2 | 0 Increased creatinine | 0 | 0 | 3 | 0 | 1 | 0 Hypophosphatemia | 0 | 0 | 6 | 1 | 2 | 0 Hypokalemia | 0 | 0 | 5 | 1 | 0 | 0 Hyperuricemia …

Application of group LASSO regression based Bayesian networks in risk factors exploration and disease prediction for acute kidney injury in hospitalized patients with hematologic malignancies.

BackgroundPatients who were diagnosed with hematologic malignancies (HM) had a higher risk of acute kidney injury (AKI). This study applies the Bayesian networks (BNs) to investigate the interrelationships between AKI and its risk factors among HM patients, and to evaluate the predictive and inferential ability of BNs model in different clinical settings.MethodsDuring 2014 and 2015, a total of 2501 inpatients with HM were recruited in this retrospective study conducted in a tertiary hospital, Shanghai of China. Patients' demographics, medical history, clinical and laboratory records on admissi

Совпадение в полном тексте источника
… For instance, when anemia, hyperuricemia, and hyponatremia were initially found on admission in patients with leukemia, the expected probability of AKI was estimated to be 53.8% based on the prior information of BNs. … When leukemia patients were initially diagnosed with anemia, hyperuricemia, and hyponatremia, the expected probability of AKI was 53.8%. If these biochemical indicators were corrected to normal level timely, the incidence of AKI would be significantly reduced to 9.9%. …

Parathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera.

Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation. It has many complications and it might increase the risk of other tumors. However, it does not cause hypercalcemia and is rarely associated with parathyroid adenoma. Here, we report on a 64-year-old female with polycythemia vera found to have hypercalcemia due to parathyroid adenoma.

Совпадение в полном тексте источника
… PV has some complications, which include thrombosis, bleeding, hepatosplenomegaly, erythromelalgia, hyperuricemia, myelofibrosis, and transformation to myelodysplasia or acute leukemia. However, hypercalcemia is not one of these complications. …

When "Myeloma" is not a Myeloma: a case report of malignant bone lymphoma.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Biochemistry did not reveal any hepatic or renal dysfunction; albumin was 3.2 g/dL [VR 3.8–5.3], lactate dehydrogenase 472 U/L [RV 67–248], and no hypercalcemia, hyperuricemia, or beta-2 microglobulin elevation. …

Patients' Perspective of Medication Adherence in Chronic Conditions: A Qualitative Study.

IntroductionAbout 50% of patients do not take their long-term therapy for chronic conditions as prescribed. Many studies have centered on patients' adherence to a specific treatment or single conditions, but few have taken all chronic conditions into consideration from a patient's perspective. This study aims to explore factors that impact on drug compliance and to identify strategies to improve this from the perspective of patients with at least one chronic condition.MethodsPatients were recruited by healthcare professionals from a hospital pharmacy, four community pharmacies, patient associa

Совпадение в полном тексте источника
… bipolar disorder Males with >2 comorbidities Participant 8 | M | 61 | Chronic obstructive pulmonary disease and cardiac arrhythmia Participant 9 | M | 71 | Crohn’s disease, ischemic heart disease, and hypothyroidism Participant 10 | M | 63 | Prostate cancer, asthma, hypertension, cardiac arrhythmia, and hyperuricemia … | Bronchiectasis, hypertension, and dyslipidemia Participant 12 | M | 70 | Parkinson Participant 13 | M | 75 | Parkinson disease, ischemic heart disease, diabetes, dyslipidemia, and depression Participant 14 | M | 77 | Hypertension, dyslipidemia and diabetes Participant 15 | M | 72 | Hypertension, hyperuricemia …

A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.

OBJECTIVES: The selected combination was based on limited evidence clinically and in vitro on the efficacy of the Favipiravir and Hydroxychl … witched to another agent or adjusted while using the investigational drug • Gout/history of Gout or hyperuricemia (above the ULN), hereditary xanthinuria or xanthine calculi of the urinary tract. INTERVENTION AND COMPARATOR: The treatment intervention would be for a maximum of 10 days from randomization and it would be as follows: Favipiravir for 10 days: Admi …

Advances in the Study of Denosumab Treatment for Osteoporosis and Sarcopenia in the Chinese Middle-Aged and Elderly Population.

Osteosarcopenia (OS) is a geriatric syndrome characterized by the concurrent presence of osteoporosis and sarcopenia, predominantly affecting the elderly population. Osteoporosis (OP) is a systemic skeletal disorder characterized by decreased bone mass, compromised bone microarchitecture, and heightened bone fragility, substantially elevating fracture risk. Sarcopenia (SP) is defined by decreased muscle mass, strength, and/or functional capacity. Both conditions are age-related degenerative diseases with overlapping pathophysiological mechanisms, commonly co-occurring in elderly individuals an

Совпадение в полном тексте источника
… Furthermore, additional studies have indicated that elevated aldosterone levels exert a dual impact on hyperuricemia and gout, thereby further complicating the clinical manifestations of osteoporosis in hypertensive patients. 56 Inflammation represents another critical link between hypertension, osteoporosis … Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout . Front Endocrinol . 2024 ; 15 : 1424207 . doi: 10.3389/fendo.2024.1424207 PMC11319118 39140032 57. Ma H , Cai X , Hu J , et al. …

Множественная миелома с психической нефропатией и негативом Бенса-Джонса Протеинурии: Редкое клиническое представление.

Множественная миелома (MM) — злокачественное расстройство плазменных клеток, которое обычно вызывает анемию, боль в костях, гиперкальцемию и почечную недостаточность. Мы сообщаем о случае 55-year-old Мужчина, у которого были в основном острые повреждения почек (АКИ), пинентопенция и системное воспаление без классических особенностей гиперкальцемии или литических повреждений костей. В частности, мочевые белки Бенса-Джонса были отрицательными, несмотря на заметно повышенную сыворотку каппа и аномальный белковый электрофорез (SPEP). Биопсия костного мозга выявила скромный плазмоцитоз, в то время

Совпадение в полном тексте источника
… 9.34 mg/dL | 0.5–0.9 mg/dL | Markedly elevated Sodium | 150 mmol/L | 135–145 mmol/L | Hypernatremia Potassium | 3.4 mmol/L | 3.5–5.0 mmol/L | Hypokalemia Calcium | 8.1 mg/dL | 8.6–10 mg/dL | Hypocalcemia Phosphate | 6.5 mg/dL | 2.5–4.5 mg/dL | Hyperphosphatemia Uric acid | 12.5 mg/dL | 3.4–7.0 mg/dL | Hyperuricemia …

Проблемы с диагностикой и оказанием неотложной медицинской помощи в случае быстро прогрессирующего заболевания лёгких, вторичного и многократного заболевания миеломой.

Одновременное представление множественной миеломы (ММ) и межститиальной болезни легких (МЛ) остается исключительно редким, при этом ограниченная литература описывает оптимальные стратегии управления для этой двойной патологии. Мы сообщаем о сложном случае 62-year-old Мужчина с недавно поставленным диагнозом MM с цитогенетикой промежуточного риска (del13q, набирающий 1q), который одновременно представил быстро прогрессирующий ILD, демонстрирующий обычную интерститальную пневмонию (МСАГВ). Пациентка 6-month Клинический курс был отмечен участием многих организаций, периодическими инфекциями, тром

Совпадение в полном тексте источника
… Renal dysfunction resulted from myeloma kidney (Lambda light chain precipitation), hyperuricemia, and sepsis. The patient experienced cascade infections from immunosuppression, prolonged hospitalization, and invasive procedures. …

Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… TLS is due to the fast lysis of malignant cells determining hyperuricemia, hyperkaliemia, hypocalcemia and hyperphosphatemia. Uric acid and calcium phosphate crystals in the renal tubules may lead to acute renal failure. … Laboratory TLS is defined as two or more of the following metabolic abnormalities: hyperuricemia, hyperkaliemia, hyperphosphatemia or hypocalcemia. …

Myelomatous ascites and pleural effusion in relapsed multiple myeloma.

Extramedullary multiple myeloma is seen in advanced and aggressive disease and occurs due to plasma cell infiltration of sites other than the bone marrow. Myelomatous ascites or pleural effusion is seen in less than 1% of cases and can be differentiated from infectious etiologies based on fluid cytology.

Совпадение в полном тексте источника
… His renal function improved significantly following treatment with cyclophosphamide 1 gm/m 2 for 2 days, pulse dexamethasone 40 mg for 5 days, and rasburicase 3 mg due to hyperuricemia and tumor lysis syndrome. During the hospital stay, the patient had significant abdominal pain and distension. …

Intravascular large B-cell lymphoma presenting with hearing loss and dizziness: A case report.

RATIONALE: Intravascular large B-cell lymphoma (IVLBCL) is a type of malignant lymphoma in which neoplastic B cells proliferate selectively within the lumina of small- and medium-sized vessels. Patients with IVLBCL frequently develop neurological manifestations during their disease course. Patients are known to often develop various neurological manifestations, but there are only a few reports of IVLBCL whose initial symptoms are deafness and/or disequilibrium. PATIENT CONCERNS: A 66-year-old Japanese man was provisionally diagnosed with sudden sensorineural hearing loss. Administration of pr

Совпадение в полном тексте источника
… His past medical history included treated hypertension and hyperuricemia. Our physical examination revealed a body temperature of 37.3°C, blood pressure of 118/93 mm Hg, pulse rate of 108/min, respiration rate of 19/min, and peripheral oxygen saturation of 100% with a 3 L/min oxygen mask. …

Marginal resection of solitary plasmacytoma in the anterior region of the mandible and dental implant rehabilitation: Report of an unusual case.

INTRODUCTION: Plasmacytoma describes a neoplastic proliferation of plasma cells affecting different groups of patients according to location, and may demonstrate heterogeneous tumor progression and survival rate. The present article describes a case of solitary plasmacytoma in the mandible. PRESENTATION OF CASE: A 57-year-old male smoker was referred to the oral and maxillofacial service with extensive injury, approximately 4-5 cm in size, involving the anterior inferior region of mandible. After confirming diagnosis of plasmacytoma through incisional biopsy, because it was a recurrent lesion

Совпадение в полном тексте источника
… Furthermore, a renal biopsy to verify the presence of Bence-Jones protein, which is considered the gold standard to diagnose multiple myeloma, as well as hyperuricemia, hypercalciuria, and signs of dehydration should be part of routine practice. …

Pleural effusion and multiple myeloma - more than meets the eye: A case report.

Multiple myeloma (MM) accounts for 1% of all cancers. It consists of malignant proliferation of plasma cells, which is often associated with hypersecretion of a monoclonal protein. Pleural effusion (PE) in MM is not an uncommon finding, comprising about 6-14% of patients with MM. The most common causes of MM-associated PE are congestive heart failure, renal failure, parapneumonic effusion and amyloidosis. In <1% of cases, the effusion is a direct result of MM, designated as myelomatous PE (MPE). MPE is usually a diagnosis of exclusion and carries a poor prognosis. Therefore, efforts should be

Совпадение в полном тексте источника
… Case report The authors describe the case of a 79-year-old white woman, with IgG/λ MM, hypertension, type 2 diabetes mellitus, dyslipidemia and hyperuricemia. MM was diagnosed two months prior admission ( Fig. 1 ). …

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.

BackgroundAponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of aponermin in patients with relapsed or refractory multiple myeloma (RRMM). To confirm the superiority of aponermin plus thalidomide and dexamethasone (aponermin group) over placebo plus thalidomide and dexamethasone (placebo group) in RRMM, a randomized, double-blinded, placebo controlled phase 3 trial was performed.MethodsFour hundred seventeen patients with RRMM who had

Совпадение в полном тексте источника
… Upper respiratory tract infection 76 (27.5) 21 (7.6) 24 (17.3) 7 (5.0) 0.02, 0.32 Increased blood urea 70 (25.4) 3 (1.1) 33 (23.7) 1 (0.7) 0.72, 0.72 Proteinuria/urinary protein detected 87 (31.5) 1 (0.4) 34 (24.5) 1 (0.7) 0.14, 0.62 Hypophosphatemia 67 (24.3) 17 (6.2) 28 (20.1) 13 (9.4) 0.34, 0.24 Hyperuricemia … 27.5) | 21 (7.6) | 24 (17.3) | 7 (5.0) | 0.02, 0.32 Increased blood urea | 70 (25.4) | 3 (1.1) | 33 (23.7) | 1 (0.7) | 0.72, 0.72 Proteinuria/urinary protein detected | 87 (31.5) | 1 (0.4) | 34 (24.5) | 1 (0.7) | 0.14, 0.62 Hypophosphatemia | 67 (24.3) | 17 (6.2) | 28 (20.1) | 13 (9.4) | 0.34, 0.24 Hyperuricemia …

Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.

A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m2 vs. twice-weekly Kd 20/27 mg/m2 based on progression-free survival (PFS) in relapsed and/or refractory multiple myeloma patients. Forty Japanese patients (once-weekly arm, n = 26; twice-weekly arm, n = 14) were randomized in A.R.R.O.W. In the Japanese subgroup of A.R.R.O.W., median PFS was 14.8 months (95% confidence interval [CI], 7.5-not evaluable [NE]) and 9.7 months (95% CI, 3.8-NE) in the once- and twice-weekly arms, respectively. The overall response rate (ORR) was 73.1% (19/26; 95% CI, 52

Совпадение в полном тексте источника
… 1 (3.8) 0 (0.0) 0 (0.0) Weight decreased 3 (11.5) 1 (3.8) 1 (7.1) 0 (0.0) Hypokalemia 2 (7.7) 1 (3.8) 3 (21.4) 1 (7.1) Cardiac failure 2 (7.7) 2 (7.7) 2 (14.3) 1 (7.1) Back pain 2 (7.7) 0 (0.0) 2 (14.3) 0 (0.0) Pruritus 2 (7.7) 0 (0.0) 2 (14.3) 0 (0.0) Hyperglycemia 3 (11.5) 1 (3.8) 1 (7.1) 0 (0.0) Hyperuricemia … 11.5) | 1 (3.8) | 1 (7.1) | 0 (0.0) Hypokalemia | 2 (7.7) | 1 (3.8) | 3 (21.4) | 1 (7.1) Cardiac failure | 2 (7.7) | 2 (7.7) | 2 (14.3) | 1 (7.1) Back pain | 2 (7.7) | 0 (0.0) | 2 (14.3) | 0 (0.0) Pruritus | 2 (7.7) | 0 (0.0) | 2 (14.3) | 0 (0.0) Hyperglycemia | 3 (11.5) | 1 (3.8) | 1 (7.1) | 0 (0.0) Hyperuricemia …

Polydatin: Pharmacological Mechanisms, Therapeutic Targets, Biological Activities, and Health Benefits.

Polydatin is a natural potent stilbenoid polyphenol and a resveratrol derivative with improved bioavailability. Polydatin possesses potential biological activities predominantly through the modulation of pivotal signaling pathways involved in inflammation, oxidative stress, and apoptosis. Various imperative biological activities have been suggested for polydatin towards promising therapeutic effects, including anticancer, cardioprotective, anti-diabetic, gastroprotective, hepatoprotective, neuroprotective, anti-microbial, as well as health-promoting roles on the renal system, the respiratory s

Совпадение в полном тексте источника
… Studies demonstrated that polydatin can decrease uric acid levels and creatinine in serum and urine [ 46 , 188 , 189 ] via the inhibition of XOD [ 52 ] in animal models of hyperuricemia. In addition, polydatin attenuated oxidative stress induced by inflammation and urates [ 52 ]. … Polydatin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation by inhibiting NF-κB/NLRP3 inflammasome activation via the AMPK/SIRT1 pathway Food Funct. 2017 8 1785 1792 10.1039/C6FO01561A 28428988 47. Peritore A.F. D’Amico R. Cordaro M. Siracusa R. Fusco R. Gugliandolo E. …